| 4.79 -0.03 (-0.62%) | 06-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.17 | 1-year : | 8.78 |
| Resists | First : | 6.14 | Second : | 7.51 |
| Pivot price | 5.57  |
|||
| Supports | First : | 3.92 | Second : | 3.26 |
| MAs | MA(5) : | 5.28  |
MA(20) : | 5.36 |
| MA(100) : | 8.34 |
MA(250) : | 24.96 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 14.5 |
D(3) : | 25.8 |
| RSI | RSI(14): 42.9 |
|||
| 52-week | High : | 78.05 | Low : | 0.36 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SCLX ] has closed above bottom band by 20.2%. Bollinger Bands are 47.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 30 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5 - 5.05 | 5.05 - 5.08 |
| Low: | 4.61 - 4.67 | 4.67 - 4.71 |
| Close: | 4.72 - 4.82 | 4.82 - 4.88 |
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
Thu, 05 Jun 2025
Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal - GlobeNewswire
Wed, 30 Apr 2025
Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule - GlobeNewswire
Wed, 30 Apr 2025
Scilex Holding Company Regains Compliance with Nasdaq Minimum Closing Bid Price Requirement - Nasdaq
Wed, 16 Apr 2025
Scilex Holding Company Announces FDA Has Approved Our - GlobeNewswire
Fri, 11 Apr 2025
Scilex Holding Company Announces 1-for-35 Reverse Stock Split - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 5 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 22.3 (%) |
| Held by Institutions | 18.7 (%) |
| Shares Short | 297 (K) |
| Shares Short P.Month | 241 (K) |
| EPS | -15.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -38.5 |
| Profit Margin | -147 % |
| Operating Margin | -557.6 % |
| Return on Assets (ttm) | -69.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -54 % |
| Gross Profit (p.s.) | 6.64 |
| Sales Per Share | 9.23 |
| EBITDA (p.s.) | -16.45 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 16 (M) |
| Levered Free Cash Flow | 43 (M) |
| PE Ratio | -0.32 |
| PEG Ratio | 0 |
| Price to Book value | -0.13 |
| Price to Sales | 0.51 |
| Price to Cash Flow | 1.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|